-transparent.png){kind=logo}
An immunohistochemical investigation of 62 human breast Cancers has been conducted using two different monoclonal antibodies, ER-ICA and ER-D 5, for the demonstration of the estrogen receptor. ER-ICA was found to be positive in 28 cases (45.9%) whereas ER-D 5 was positive in 41 cases (68.3%). In 34 cases, the results were compared to results of a biochemical assay that employed dextran-coated charcoal. The overall concordance between the ER-ICA and the DCC was 78.8%, whereas ER-D 5 and DCC was 60.6%. We thus have concluded that ER-ICA is the more sensitive antibody for evaluating the estrogen receptor status in human breast cancer cases by this immunohistochemical analysis.
M Hori, and
M Furusato, and
S Aizawa, and
H Tanaka, and
K Uchida
January 1993,
American journal of clinical pathology,
M Hori, and
M Furusato, and
S Aizawa, and
H Tanaka, and
K Uchida
January 1973,
Archivum chirurgicum Neerlandicum,
M Hori, and
M Furusato, and
S Aizawa, and
H Tanaka, and
K Uchida
September 1975,
Journal of the National Cancer Institute,
M Hori, and
M Furusato, and
S Aizawa, and
H Tanaka, and
K Uchida
January 1984,
Progress in clinical pathology,
M Hori, and
M Furusato, and
S Aizawa, and
H Tanaka, and
K Uchida
December 1990,
Molecular and cellular endocrinology,
M Hori, and
M Furusato, and
S Aizawa, and
H Tanaka, and
K Uchida
May 2019,
Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition,
M Hori, and
M Furusato, and
S Aizawa, and
H Tanaka, and
K Uchida
August 1988,
Human pathology,
M Hori, and
M Furusato, and
S Aizawa, and
H Tanaka, and
K Uchida
February 1992,
Cancer,
M Hori, and
M Furusato, and
S Aizawa, and
H Tanaka, and
K Uchida
August 2021,
JAAD case reports,
M Hori, and
M Furusato, and
S Aizawa, and
H Tanaka, and
K Uchida
January 2000,
Breast cancer (Tokyo, Japan),
